• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Incyte Corp (NQ: INCY )

    67.79 -0.80 (-1.17%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,635,372
    Open 69.33
    Bid (Size) 67.79 (10)
    Ask (Size) 70.49 (4)
    Prev. Close 68.59
    Today's Range 64.74 - 69.33
    52wk Range 50.27 - 70.36
    Shares Outstanding 222,430,635
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance
    Incyte reported Q2 revenue of $1.04 billion, beating consensus, with Jakafi revenue at $705.9 million and Opzelura revenue up 52%. Despite an adjusted EPS loss, the company updated its 2024 Jakafi... 
    Via Benzinga
    Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
    From Incyte
    Via Business Wire

    Performance

    YTD
    +3.58%
    +3.58%
    1 Month
    +11.37%
    +11.37%
    3 Month
    +30.24%
    +30.24%
    6 Month
    +14.36%
    +14.36%
    1 Year
    +6.39%
    +6.39%

    More News

    Read More
    Analyst Ratings For Incyte
    Via Benzinga
    Looking for growth without the hefty price tag? Consider NASDAQ:INCY.
    Via Chartmill
    NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    Via Chartmill
    NASDAQ:INCY is not too expensive for the growth it is showing.
    Via Chartmill
    Analyst Expectations For Incyte's Future
    Via Benzinga
    Despite its growth, NASDAQ:INCY remains within the realm of affordability.
    Via Chartmill
    S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday?
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Incyte to Report Second Quarter Financial Results
    From Incyte
    Via Business Wire
    The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024
    Via InvestorPlace
    7 Cheap Biotech Stocks With Major Upside Potential
    Via InvestorPlace
    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte
    Via Business Wire
    3 Highly Rated Biotech Stocks for Your July Buy List
    Via InvestorPlace
    This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
    Via Benzinga
    Stocks Chop As Wall Street Unpacks Powell Comments
    Via Talk Markets
    Topics Economy
    Exposures Interest Rates
    7 Undervalued Biotech Stocks to Buy for Big-Time Returns
    Via InvestorPlace
    For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
    Via Chartmill
    Nasdaq 100, S&P 500 Close At Record Highs As Tech Stocks Reclaim Dominance: Thursday's Gainers & Losers
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Incyte Announces Final Results of Tender Offer
    From Incyte Corporation
    Via Business Wire
    Incyte Announces Preliminary Results of Tender Offer
    From Incyte Corporation
    Via Business Wire
    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte
    Via Business Wire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Incyte Completes Acquisition of Escient Pharmaceuticals
    From Incyte
    Via Business Wire
    When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
    Via Chartmill
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.